Clinical trials: Leukaemia Relapse
Leukemia, Myeloid, Chronic, AML
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
- Conditions
- Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00167167
- Testing
- Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
AML
Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML
This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia
- Trial name
- NCT05463640
- Testing
- ADGRE2 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Lymphoma
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00005040
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a single-arm, open-label, phase I study (safety and dose escalation) of autologous Chimeric Antigen Receptor (CAR) T-cells targeting CD19 in patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL).
- Trial name
- NCT04653493
- Testing
- CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Iran
- Volunteers
- 22 people
- Sponsor
- Sabz Biomedicals
AML, Childhood
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
- Trial name
- NCT03825367
- Testing
- Nivolumab, 5-azacytidine
- Where
- 12 sites in United States
- Volunteers
- 13 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
This phase I/II trial is studies the side effects of giving therapeutic allogeneic lymphocytes together with aldesleukin and to see how well it works in treating patients with high-risk or recurrent myeloid leukemia after…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00052598
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Pediatric B-ALL
JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of…
- Trial name
- NCT07406178
- Testing
- JY509 universal NK cell injection
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
- Trial name
- NCT04226989
- Testing
- CT-RD06
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cancer is the uncontrolled growth of human cells. The growth of normal human cells is controlled by multiple mechanisms. Panobinostat belongs to a class of chemotherapy drugs called "histone deacetylase (HDAC) inhibitors." HDAC…
- Trial name
- NCT02676323
- Testing
- Panobinostat, Fludarabine, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Stem cell transplant is an important therapeutic option for pediatric patients with relapsed or refractory leukemia. Although, full myeloablative transplants are widely used for patients with acute leukemia, myeloablative…
- Conditions
- Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
- Trial name
- NCT01041508
- Testing
- Clofarabine, Total Body Irradiation, Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine